RxDoctor Payments DataLook up a doctor →

Marc Cohen, MD

Cardiovascular Disease · Newark, NJNPI 1376510578

Payments from drug & device makers

$1,037,692in general payments, 2019–2025

Across 918 payments — averaging $1130.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$336K
  • Edwards Lifesciences$211K
  • Boehringer Ingelheim$108K
  • AstraZeneca$94K
  • Lilly USA, LLC$71K
  • Sanofi-aventis U.S. LLC$58K
  • plus $159K from 39 others

What the payments were for

  • Consulting fees$64,5108%
  • Speaking & faculty fees$621,50882%
  • Travel & lodging$57,4198%
  • Food & beverage$18,0302%
  • Education$170%
  • Gifts$490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,037,692 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$73,708
Medicare patients
226
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$64,268
XareltoRivaroxaban44$47,816
EntrestoSacubitril/Valsartan40$47,812
Repatha SureclickEvolocumab37$41,562
MultaqDronedarone Hcl29$30,974
BrilintaTicagrelor36$30,518
JardianceEmpagliflozin26$23,178
Praluent PenAlirocumab14$8,428
Ezetimibe164$4,986
Atorvastatin Calcium171$1,978
ClopidogrelClopidogrel Bisulfate122$1,871
Nitroglycerin11$1,215
Valsartan75$1,206
Digoxin40$1,095
Rosuvastatin Calcium64$1,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$64,26860 claims
Johnson & JohnsonXarelto$336,396$47,81644 claims
NovartisEntresto$8,408$47,81240 claims
Sanofi-aventis U.S. LLCMultaq$58,042$30,97429 claims
AstraZenecaBrilinta$94,289$30,51836 claims
Boehringer IngelheimJardiance$107,965$23,17826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Newark

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →